MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

MannKind Corporation

Westlake Landmark office park
Westlake Village, CA
United States

http://www.mannkindcorp.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees153

Key Executives

NameTitlePayExercisedAge
Dr. Michael E. Castagna Pharm.D.CEO & Director378.41kN/A41
Dr. David B. Thomson Ph.D., J.D.Corp. VP, Gen. Counsel & Corp. Sec.458.68k424.8k51
Mr. Steven BinderChief Financial OfficerN/AN/AN/A
Mr. Joseph KocinskyChief Technology OfficerN/AN/A54
Ms. Courtney BartonChief Compliance Officer and VPN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.